QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

GPCR

QT70Structure Therapeutics Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
44.51
-0.49-1.09%
OverviewShort InterestFilings
GPCRQT70Structure Therapeutics Inc.·NASDAQ
OverviewShort InterestFilings
44.51-1.09%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own6.11%
Shs Outstand213.22M
Perf Week2.79%
Market Cap2.59BForward P/E-EPS next Y-1.94Insider Trans-0.02%Shs Float-Perf Month24.05%
Enterprise Value2.28BPEG0.94EPS next Q-0.39Inst Own-Short Float-Perf Quarter-11.79%
Income-135483148.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-27.87%
Sales-P/B2.25EPS next Y-36.08%ROA-11.31%Short Interest-Perf YTD-36.00%
Book/sh6.79P/C-EPS next 5Y-ROE-15.14%52W High94.90 -53.10%Perf Year112.26%
Cash/sh6.84P/FCF-EPS past 3/5Y-ROIC-14.44%52W Low15.80 181.71%Perf 3Y-
Dividend Est.-EV/EBITDA-13.59Sales past 3/5Y-Gross Margin0.00%Volatility3.31% 3.87%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM32.91%Oper. Margin0.00%ATR (14)2.31Perf 10Y-
Dividend Ex-Date-Quick Ratio26.16Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.57Recom2.00
Dividend Gr. 3/5Y-Current Ratio26.16EPS Q/Q-29.63%SMA2010.07%Beta0.76Target Price111.60
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA504.13%Rel Volume1.39Prev Close45.00
Employees163LT Debt/Eq0.00EarningsAug 06SMA200-7.68%Avg Volume814.66KPrice44.51
IPO DateFeb 03, 2023Option/ShortYes / YesEPS/Sales Surpr.10.26% -Net Debt/EBITDA1.85Volume1,135,481Change-1.09%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-11-26ReiteratedH.C. Wainwright$90 → $70
Apr-27-26InitiatedCanaccordBuy$101
Mar-17-26ReiteratedBMO CapitalOutperform$100 → $145
Jan-20-26ReiteratedGuggenheimBuy$140
Jan-19-26ReiteratedGoldman Sachs$102
Dec-19-25ReiteratedH.C. Wainwright$60 → $90
Dec-12-25ReiteratedMorgan StanleyOverweight$118 → $125
Dec-11-25ReiteratedJefferiesBuy$125
Dec-08-25ReiteratedStifel Nicolaus$50 → $90
Dec-02-25ReiteratedStifel Nicolaus$50
Latest News
Jun-11-26
Jun-11-2601:03PM
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)SeekingAlpha
01:03PM
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)SeekingAlpha
07:49AM
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga
07:49AM
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga
06:09AM
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70Benzinga
06:09AM
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A400
Gross Profit-400
Selling, General and Administrative Excl. Other624933
Research and Development22510970
Other Operating Expense-300
Operating Income-288-158-103
Interest Expense0013
Unusual Expense
———
Non-Operating Income (Expense)-147-36-27
Net Income Before Taxes-141-122-89
Income Taxes100
Consolidated Net Income-141-123-90
Net Income From Continuing Operations-141-123-90
Net Income-141-123-90
EPS (Recurring)-2.40-2.34-2.43
EPS (Basic, Before Extraordinaries)-2.40-2.34-2.43
EPS (Diluted)-2.40-2.34-2.43
EBITDA-137-121-76
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding595337
Market Capitalization4,103——
Operating Lease Expense
———
Insider Trading Volume
$50.31$46.67$43.03$39.38$35.74● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FMR LLC10 percent owner, other: See Remark 1Apr 14 '26Sale0.0017,45202,736Apr 16 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Jan 15 '26Sale0.0017,45204,103Jan 20 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Dec 08 '25Sale0.0052,35600Dec 10 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Jul 30 '25Sale0.0026,31001,515,558Aug 01 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Feb 06 '25Sale0.004100Feb 10 12:00 AM
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 12 '24Option Exercise0.42300,000126,000793,346Jun 14 12:00 AM
Stevens Raymond CCHIEF EXECUTIVE OFFICERJun 10 '24Sale0.00185,00000Jun 12 12:00 AM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Option Exercise0.34212,40072,216213,800Jun 05 12:00 AM
Lin XichenCHIEF SCIENTIFIC OFFICERJun 03 '24Sale0.0035,40000Jun 05 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Mar 14 '24Sale0.0021,99701,541,868Mar 18 12:00 AM
FMR LLC10 percent owner, other: See Remark 1Feb 13 '24Sale0.0052501,563,865Feb 15 12:00 AM
FMR LLC10% OwnerDec 05 '23Sale0.0017,45402,733Dec 07 12:00 AM
FMR LLC10% OwnerOct 18 '23Sale0.0017,45404,101Oct 23 12:00 AM
Farid RamyDirectorFeb 07 '23Buy0.00275,0000275,000Feb 09 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR